Metabolite Profiling and Identification Studies
As the field of pharmaceutical research continues to evolve, the importance of understanding metabolites and their impact on drug development cannot be overstated. As a research service provider dedicated to advancing research on autoimmune diseases and inflammation, we provide comprehensive metabolite profiling and identification research services.
Introduction to Metabolite Profiling and Identification Studies
Metabolite profiling and identification studies involve the comprehensive analysis of metabolites, including their intermediates, in investigational products. The primary goal is to understand the routes of elimination, predict drug-drug interactions, and anticipate safety concerns in humans. By gaining insight into the metabolic fate of a drug, researchers can better assess its efficacy, safety, and potential as a therapeutic agent.
In the context of autoimmune diseases and inflammation, metabolite profiling and identification studies play a crucial role in unraveling the complex mechanisms underlying these conditions. By examining the metabolites involved, researchers can gain a deeper understanding of the metabolic pathways associated with these diseases, potentially leading to the development of more targeted and effective therapies.
Fig.1 Metabolite profiling and identification by LC-MS/MS. (Reddy G.N., et al., 2021)
Application of Metabolite Profiling and Identification Studies
- In the development of immunomodulatory drugs for autoimmune diseases, metabolite profiling can reveal the metabolic pathways influenced by these agents. This information helps in evaluating the drug's efficacy and potential side effects, leading to safer and more effective therapies.
- Metabolite profiling studies can aid in the identification of metabolites responsible for adverse drug reactions or toxicity. By understanding the metabolic pathways leading to the formation of these metabolites, researchers can modify drug structures or dosing regimens to minimize these risks.
Our Services
Our company recognizes the importance of metabolite profiling and identification research and is committed to developing innovative technologies to support the development of therapies for autoimmune diseases and inflammation. With extensive experience, we aim to meet any of your needs during the research and development process.
| Animal Species |
|---|
| Mouse, Rat, Pig, Dog, Monkey, Others |
| Dosing Routes |
| Oral administration (PO), Intraperitoneal (IP), Intravenous (IV), Intramuscular (IM), and Subcutaneous (SC), Others |
| Techniques of Metabolite Profiling and Identification Studies |
|
| Analysis Software |
| ADMETlab 2.0, SwissADME, MassLynx, Xcalibur, MetabolitePilot, Others |
Content of Metabolite Profiling and Identification Studies
Metabolite Identification
Our company uses advanced analytical techniques such as NMR and mass spectrometry to conduct comprehensive identification and characterization of metabolites in research products. This aids in understanding the metabolic fate of drugs and identifying potential toxic metabolites.
Metabolite Quantification
By accurately quantifying metabolites in a variety of sample matrices, including plasma, urine, and feces, we can determine the pharmacokinetics and levels of specific metabolites, providing valuable information for dose optimization and therapy monitoring.
Pathway Analysis
We study metabolic pathways relevant to autoimmune diseases and inflammation, including identifying key enzymes, intermediates, and regulatory molecules involved in these pathways to develop targeted therapies.
Why Choose Us?
As an integrated CRO, we have the capabilities and resources to provide professional communication and problem-solving support to ensure that we can quickly respond to the changing needs of your autoimmune diseases and inflammation research projects. If you are interested in our services, please don't hesitate to contact us.
Reference
- Reddy Gangireddy Navitha, Chenkual Laltanpuii, and Rajesh Sonti. "Review on in vivo profiling of drug metabolites with LC-MS/MS in the past decade." Bioanalysis 13.22 (2021): 1697-1722.